Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025
Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025 |
| [16-December-2025] |
NEW TAIPEI CITY, Dec. 15, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919), a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics, announced that preclinical research involving CBL-514 was presented at the 25th Annual Congress of the Taiwan Medical Association for the Study of Obesity (TMASO 2025), held jointly with the 9th Japan–Korea–Taiwan Symposium on Obesity at National Taiwan University Hospital.
The congress brought together leading academic and clinical experts from Taiwan, Japan, and Korea to examine emerging challenges in obesity management, particularly in the context of widespread adoption of incretin-based therapies. Scientific discussions increasingly emphasized the need for multi-mechanism strategies that extend beyond appetite regulation and address adipose tissue biology, fat distribution, and post-treatment weight dynamics. Scientific Context: Beyond Weight Loss Toward Durability and Fat Biology These perspectives reflect growing recognition that weight rebound following discontinuation of incretin-based therapies remains a clinically relevant challenge, and that fat quality and visceral adiposity may play an important role in long-term outcomes. Preclinical Study: CBL-514 in Combination With a Dual Incretin Receptor Agonist The study evaluated CBL-514, a small-molecule drug that selectively induces adipocyte apoptosis, in combination with a dual GLP-1/GIP receptor agonist (tirzepatide) in diet-induced obese (DIO) rat models. The study design included an observation period following incretin withdrawal, enabling assessment of weight maintenance and adipose tissue outcomes beyond active incretin treatment. Under the specific conditions of the animal model, the combination group demonstrated statistically significant differences compared with incretin monotherapy across multiple parameters, including:
Mechanistic Rationale: Targeting Adipocyte Number as a Complement to Incretin Therapy CBL-514 was described as targeting intracellular signaling pathways, including DYRK1B, leading to decreased anti-apoptotic signaling and increased pro-apoptotic activity in adipocytes. From a scientific perspective, this mechanism provides a rationale for exploring whether combining incretin-based therapies with agents that directly modulate adipose tissue biology could influence fat distribution and post-treatment weight dynamics. Dr. Chou emphasized that additional research is required to determine optimal treatment sequencing, duration, and patient selection, as well as to assess potential clinical relevance in humans. Implications for Future Obesity Research and Drug Development Caliway noted that the study supports further investigation into whether adipocyte-targeted mechanisms may complement existing incretin pipelines, including potential roles in combination or maintenance-phase strategies, subject to future clinical evaluation. About CBL-514 As of May 2025, 10 clinical trials with a total of 520 subjects have been completed with all efficacy and safety endpoints met. Caliway is currently investigating multiple indications for CBL-514, including non-surgical fat reduction, moderate-to-severe cellulite, and weight management. CBL-514D, the same active pharmaceutical ingredients (APIs) but under different formulation, is being studied for additional indications such as Dercum's disease and more. Media Contact: About Caliway Biopharmaceuticals Disclaimer
SOURCE Caliway | ||
Company Codes: Taiwan:6919,TWSE:6919 |
View original content to download multimedia:
